Advertisement

Cutaneous Oncology

Where We Are and Where We Are Going
Published:October 27, 2022DOI:https://doi.org/10.1016/j.det.2022.08.001
      Figure thumbnail fx1
      Stanislav N. Tolkachjov, MD, FAAD, FACMS, Editor
      The issue also outlines current standard treatments, including Mohs micrographic surgery and nail surgery, with a focus on understanding and executing proper surgical technique, improvements in histopathologic evaluation, and approaches to tumors in special sites, such as the nails and the genitalia. While Mohs surgery has been increasingly used in the treatment of melanoma, this issue provides a discussion of the background to current melanoma treatment guidelines and suggests why these should at least be reevaluated in the context of margins and surgical standards of care.
      Tumor-specific articles include squamous cell carcinoma, basal cell carcinoma, melanoma, Merkel cell carcinoma, adnexal and sebaceous carcinomas, mesenchymal tumors, as well as B-cell and T-cell lymphomas. Special populations like patients with immunosuppression and the pediatric age groups are separately discussed with a focus on genodermatoses and skin cancer syndromes. The issue is rounded off by new and established chemoprevention techniques reviewed from a perspective of basic and translational research to clinical use.
      The issue is written by a group of highly respected experts in each field presented with a practical approach for clinicians to easily understand and apply to their daily practices. The information is current, referenced, and accompanied by well-designed illustrations and high-quality images allowing readers to reference summarized materials and key points. Readers of the issue should be able to understand current and evolving approaches to cutaneous oncology in the general and special populations, and the issue should serve as a point of reference in the daily clinical practice of managing patients with cutaneous malignancies.